The pricing outcomes negotiated in these agreements will likely have a far bigger impact on access outcomes than anything implemented as a result of the Health Technology Assessment Review. …
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News -
Percheron turns to former Arovella chief Michael Baker for next phase of HMBD 002 development
August 10, 2026 - - Latest News -
Australian company points to encouraging survival signal in mesothelioma CAR-T study
August 10, 2026 - - Australian Biotech -
GBMA White Paper calls for reforms to strengthen supply chain resilience
August 10, 2026 - - Latest News -
Achieving value is meaningless if it undermines access to medicines
August 10, 2026 - - Latest News -
New Zealand's ACT announces plan for pharmacies to do a lot more, but also ownership and location reform
August 10, 2026 - - Latest News -
France the first to provide comprehensive reimbursement for GLP-1s for weight loss while Australia looks on
August 10, 2026 - - Latest News